Abstract: In treated patients, two patterns of resistance associated mutations (RAMs) were observed: (1) K65R (9.8%), L74V (7.4%), M184V (7.4%), Q151M (5%), and thymidine analogue mutations (TAMs) (9.3%) including T215Y (5.5%), in patients who underwent ddI + d4T + NVP.
Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso.
PMID: 17725411
2007
AIDS research and human retroviruses
Abstract: Two samples harbored known resistance mutations: M184V RT mutation in one and Q151M with M184V in the other.
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Result: In comparison, mutations such as K65R, K70E, L74V, Q151M, and M184V increase the selectivity of RT for incorporation of natural deoxynucleoside triphosphate substrate versus the NRTI-triphosphate.
Study of drug resistance among 78 antiretroviral treatment-naive patients with HIV-1 subtype B infection in central China.
PMID: 22504392
2007
Drug discoveries & therapeutics
Abstract: The major mutations, which were mainly K103N and Q151M, were less frequent in China than those in other countries.
Bleomycin has antiviral properties against drug-resistant HIV strains and sensitises virus to currently used antiviral agents.
PMID: 16332431
2006
International journal of antimicrobial agents
Abstract: Three clinically relevant mutant HIV variants, including one containing the Q151M mutation conferring multinucleoside resistance, were equally as sensitive to BLM as the wild-type HXB2 strain.
Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia.
PMID: 16404607
2006
Medical microbiology and immunology
Abstract: A patient with Q151M mutation complex was also detected.
In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
PMID: 16436719
2006
Antimicrobial agents and chemotherapy
Abstract: Insertions at amino acid position 69 and Q151M mutations (with or without M184V) reduced SPD754 susceptibility 5.2-fold and 14- to 16-fold, respectively (these changes gave values comparable to or less than the corresponding values for zidovudine, lamivudine, abacavir, and didanosine).
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Abstract: In this study, we measured the antiviral activity of FTC and 3TC against HIV-1 containing K65R, Q151M, and K65R/Q151M mutations.
Abstract: Overall, this study demonstrated that K65R and K65R/Q151M related drug resistance to FTC and 3TC was mainly due to a significant decrease in the rate of incorporation.
Abstract: The Q151M mutation confers reduced susceptibility to many of the approved anti-HIV nucleoside analogues with the exception of 3TC and teno
Abstract: The double mutation K65R/Q151M has been shown to be more resistant to many NRTIs than either of the single mutations alone.
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
PMID: 16540937
2006
Journal of acquired immune deficiency syndromes (1999)
Abstract: An increased genetic barrier was calculated for I82A (subtypes C and G), V108I (subtype G), V118I (subtype G), Q151M (subtypes D and F), L210W (subtypes C, F, G, and CRF02_AG), and P225H (subtype A) (P < 0.001 compared with subtype B).
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Abstract: Among genotypic correlates, the presence of M184V and NAMs seems to be protective for the emergence of K65R, while a strong positive correlation was found with the Q151M complex mutation.
Abstract: However, exposure to abacavir and/or efavirenz, presence of Q151M and/or L100I, and prior AIDS may favor the selection of this mutation.
HIV mutation literature information.
PMID: 
2007
Journal of medical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT